Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022068585 - LIPID MICROSPHERE COMPOSITION AND PREPARATION METHOD THEREFOR

Publication Number WO/2022/068585
Publication Date 07.04.2022
International Application No. PCT/CN2021/118446
International Filing Date 15.09.2021
IPC
A61K 9/107 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
A61K 31/337 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
337having four-membered rings, e.g. taxol
A61K 31/34 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/365 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
A61K 31/4745 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 45/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
CPC
A61K 31/337
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
337having four-membered rings, e.g. taxol
A61K 31/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61K 47/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
24containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Applicants
  • 北京诺康达医药科技股份有限公司 NKD PHARM CO., LTD [CN]/[CN]
Inventors
  • 左保燕 ZUO, Baoyan
  • 马丽端 MA, Liduan
  • 陈成军 CHEN, Chengjun
  • 张超 ZHANG, Chao
  • 尚丽霞 SHANG, Lixia
  • 陶秀梅 TAO, Xiumei
Agents
  • 北京路浩知识产权代理有限公司 CN-KNOWHOW INTELLECTUAL PROPERTY AGENT LIMITED
Priority Data
202011061934.830.09.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) LIPID MICROSPHERE COMPOSITION AND PREPARATION METHOD THEREFOR
(FR) COMPOSITION DE MICRO-SPHÈRE LIPIDIQUE ET SON PROCÉDÉ DE PRÉPARATION
(ZH) 脂质微球组合物及其制备方法
Abstract
(EN) A lipid microsphere composition and a preparation method therefor. The lipid microsphere composition contains a pharmaceutical phospholipid complex, and contains egg yolk phosphatidylglycerol as a stabilizer, wherein the phospholipid is egg yolk lecithin E80. The egg yolk lecithin E80 is selected to prepare the pharmaceutical phospholipid complex, and the egg yolk phosphatidylglycerol is selected as the stabilizer, so that the prepared lipid microsphere can significantly improve the encapsulation efficiency and stability, and particularly has a better effect on medicines with a poorer fat solubility.
(FR) La présente invention concerne une composition de micro-sphère lipidique et son procédé de préparation. La composition de micro-sphère lipidique contient un complexe phospholipidique pharmaceutique, et contient du phosphatidylglycérol de jaune d’œuf comme stabilisant, le phospholipide étant la lécithine E80 de jaune d’œuf. La lécithine E80 de jaune d’œuf est sélectionnée afin de préparer le complexe phospholipidique pharmaceutique, et le phosphatidylglycérol de jaune d’œuf est sélectionné comme stabilisant, de sorte que la micro-sphère lipidique préparée peut améliorer significativement l’efficacité et la stabilité d’encapsulation et, en particulier, avoir un meilleur effet sur les médicaments ayant une solubilité inférieure dans les graisses.
(ZH) 一种脂质微球组合物及其制备方法。脂质微球组合物含有药物磷脂复合物,并且含有作为稳定剂的蛋黄磷脂酰甘油;其中,所述磷脂为蛋黄卵磷脂E80。选用蛋黄卵磷脂E80制成药物磷脂复合物,选用蛋黄磷脂酰甘油作为稳定剂,这样所制成的脂质微球可以显著地提高包封率和稳定性,尤其是对于脂溶性较差的药物效果更佳。
Related patent documents
Latest bibliographic data on file with the International Bureau